Menarini Stemline

Menarini Stemline is the U.S.-based oncology subsidiary of the Menarini Group, a leading international pharmaceutical and diagnostics company. The company is dedicated to the discovery, development, and commercialization of novel oncology therapeutics that target unmet medical needs in both solid tumors and hematologic malignancies. Following its acquisition by the Menarini Group in 2020, Stemline has expanded its global footprint, leveraging Menarini's extensive commercial infrastructure in Europe and emerging markets. The company currently markets two major FDA-approved therapies: ELZONRIS for BPDCN and ORSERDU for ESR1-mutated metastatic breast cancer, while maintaining a robust pipeline of targeted small molecules and biologics.